Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY

Reuters2026/08/10 12:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Theravance Biopharma posted a Q2 GAAP net loss of USD 5.9 million, swinging from a year-earlier profit of USD 54.8 million.
Revenue rose 11% year over year to USD 20.7 million, entirely from Viatris collaboration revenue tied to YUPELRI.
R&D expense fell to USD 4.7 million from USD 10.5 million; SG&A dropped to USD 14.2 million from USD 18.4 million.
Transaction-related costs tied to the Zymeworks deal totaled USD 6.1 million; restructuring expense was USD 4 million.
Zymeworks agreed to buy the company for USD 17 per share in cash plus a CVR; closing is expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF22343) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY

You may also like

Crypto prices